

CSD/SE/BM/2021-22
June 8, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. June 8, 2021, approved the following along with other business matters.

1. Financial Results

Taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.

2. Dividend

The Board recommended a final dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021.

3. e-Annual General Meeting and Record date

- (i). The 3rd e-Annual General Meeting of the members of the Company will be held on Tuesday, August 31, 2021 through VC/ OAVM.

Suven Pharmaceuticals Limited

- (ii). The Board approved the **August 17, 2021 as record date** for the purposes of the Annual General Meeting and final dividend. The final dividend will be paid on and from September 07, 2021, within 30 days from the date of approval by members in the AGM.

Further, we are enclosing herewith the following documents:

- 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2021
- 2) Auditor's Reports on the financial results as mentioned above
- 3) Declaration in respect of Audit Reports with unmodified opinion and
- 4) A copy of the News Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 1:00 P.M.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Encl: as above

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH 2021 & UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2021
Rs. in lakhs

Sl. No.	PARTICULARS	STANDALONE				
		For the Quarter Ended			For the year ended	
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020
		Refer note .10	Un-Audited	Refer note .10	Audited	Audited
	(1)	(2)	(3)	(4)	(5)	
1	Income					
	Revenue from operations	25,916.48	27,493.32	18,476.45	100,971.85	83,378.97
	Other Income	329.82	484.29	534.00	1,423.70	1,811.73
	Total income	26,246.30	27,977.61	19,010.45	102,395.55	85,190.70
2	Expenses					
	a) Cost of materials consumed	8,737.46	7,975.82	6,424.21	31,031.50	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	398.28	(1,354.57)	(1,127.24)	(837.30)	(1,105.44)
	d) Employee benefits expense	1,651.27	2,134.71	1,737.70	7,623.30	6,510.44
	e) R & D expense	150.63	265.85	340.78	1,105.75	1,413.14
	f) Finance costs	187.03	191.03	651.22	914.37	1,866.23
	g) Depreciation and amortisation expenses	831.47	875.75	696.39	3,163.58	2,350.69
	h) Manufacturing Expenses	4,468.31	3,551.28	2,520.33	13,378.94	10,384.42
	i) Other Expenses	1,141.26	1,186.80	923.09	4,617.49	3,987.84
	Total expenses	17,565.71	14,826.67	12,166.48	60,997.63	49,431.67
3	Profit before exceptional items & Tax	8,680.59	13,150.94	6,843.97	41,397.92	35,759.03
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax	8,680.59	13,150.94	6,843.97	41,397.92	35,759.03
6	Tax Expenses			-		
	a) Current tax	1,834.65	3,444.22	1,349.07	10,171.51	8,880.94
	b) Deferred tax	400.73	(56.76)	170.83	361.72	(129.93)
7	Net Profit/ (Loss) for the period/ year	6,445.21	9,763.48	5,324.07	30,864.69	27,008.02
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(29.87)	(27.33)	(18.50)	(111.85)	(109.31)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	7.52	6.87	4.65	28.15	27.51
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(22.35)	(20.46)	(13.85)	(83.70)	(81.80)
9	Total Comprehensive Income for the period	6,422.86	9,743.02	5,310.22	30,780.99	26,926.22
10	Paid-up equity share capital (Face value of Rs.1/- each)	2,545.65	2,545.65	1,272.82	2,545.65	1,272.82
11	Other Equity	-	-	-	103,972.68	77,010.16
12	Earning Per Share (EPS)-Restated, ref note No: 4 (Face value of Rs.1/- each)					
	a) Basic	2.53	3.84	2.09	12.12	10.61
	b) Diluted	2.53	3.84	2.09	12.12	10.61
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)



		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020
		Refer note .10	Un-Audited	Refer note .10	Audited	Audited
	(1)	(2)	(3)	(4)	(5)	
1	Income					
	Revenue from operations	25,916.48	27,493.32	18,476.45	100,971.85	83,378.97
	Other Income	329.82	484.29	534.00	1,423.70	1,811.73
	Total income	26,246.30	27,977.61	19,010.45	102,395.55	85,190.70
2	Expenses					
	a) Cost of materials consumed	8,737.46	7,975.82	6,424.21	31,031.50	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	398.28	(1,354.57)	(1,127.25)	(837.30)	(1,105.45)
	d) Employee benefits expenses	1,651.27	2,134.71	1,737.70	7,623.30	6,510.44
	e) R & D Expenses	150.63	265.85	340.79	1,105.75	1,413.15
	f) Finance costs	187.03	191.03	652.59	914.37	1,991.52
	g) Depreciation and amortisation expenses	831.47	875.75	696.39	3,163.58	2,350.69
	h) Manufacturing Expenses	4,468.31	3,551.28	2,520.33	13,378.94	10,384.42
	i) Other Expenses	1,141.48	1,187.73	924.44	4,621.60	3,991.66
	Total expenses	17,565.93	14,827.60	12,169.20	61,001.74	49,560.78
3	Profit before exceptional items, Tax & share in profit/(Loss) of Associates	8,680.37	13,150.01	6,841.25	41,393.81	35,629.92
4	Add : Share of profit/(Loss) of Associates	1,866.60	1,599.98	2,096.89	5,373.60	4,821.26
5	Profit before exceptional items, Tax	10,546.97	14,749.99	8,938.14	46,767.41	40,451.18
6	Exceptional Items	-	-	-	-	-
7	Profit before Tax	10,546.97	14,749.99	8,938.14	46,767.41	40,451.18
8	Tax Expenses					
	a) Current tax	1,834.65	3,444.22	1,349.07	10,171.51	8,880.94
	b) Deferred tax	400.73	(56.76)	170.83	361.72	(129.93)
9	Net Profit/ (Loss) for the period/year	8,311.59	11,362.53	7,418.24	36,234.18	31,700.17
10	Other Comprehensive Income					
10.a	(i) Items that will not be reclassified to profit or loss	(29.87)	(27.33)	(18.50)	(111.85)	(109.30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	7.52	6.87	4.65	28.15	27.51
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(22.35)	(20.46)	(13.85)	(83.70)	(81.79)
11	Total Comprehensive Income for the period	8,289.24	11,342.07	7,404.39	36,150.48	31,618.38
12	Paid-up equity share capital (Face value of Rs.1/- each)	2,545.65	2,545.65	1,272.82	2,545.65	1,272.82
13	Other Equity	-	-	-	115,535.18	83,203.45
14	Earning Per Share (EPS)-Restated ,ref note No: 4 (Face value of Rs.1/- each) :					
	a) Basic	3.27	4.46	2.91	14.23	12.45
	b) Diluted	3.27	4.46	2.91	14.23	12.45
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(Annualised)



Notes 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8 th June,2021 . The results for the year ended March 31 ,2021 has been audited and for the quarter ended March 31,2021 has been reviewed by the statutory auditors of the company

2) The Board has recommended a final dividend of Rs.1.00 per share (i.e @ 100.00% on paid up one equity share of Rs.1.00 each) for the financial year 2020-21 subject to the approval of the share holders at the ensuing Annual General Meeting(AGM) of the company. This final dividend is in addition to the Interim dividend of Rs.1.00 per share (100% of one equity share) already paid. With this final dividend the total dividend for the year 2020-21 would be Rs.2.00 per share (i.e 200.00% of one equity share)

3) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

4) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc and Associate Rising Pharma Holdings, Inc

5) The Board has allotted the Bonus shares at 1:1 ratio in it's Board meeting held on 29th September ,2020 . Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paidup capital on account of Bonus issue of Rs.1272.82 lakhs has been appropriated from Share premium account.

6) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

7) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06,2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Suven Life Sciences Limited (SLSL) to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

8) The COVID-19 did have some impact on the business and research operations in India starting March 2021 and continues to impact in terms of employee absenteeism (around 20%), adjustment of shifts due to lock down, material movements and increase in raw material cost due to shortage of oxygen. However, there was no major impact on our subsidiary, Suven Pharma, Inc., USA.

9) Pursuant to a fire accident on 26th April, 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended 31st March 2021, the company has written off net book value of assets aggregating Rs 128.80 Lakhs and recognised a minimum insurance claim receivable for equivalent amount.

10) The figures for the current quarter and quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of full financial year ended March 31,2021 and March 31, 2020, respectively and published year to date figures upto 3rd quarter ended 31st December 2020 and 31st december 2019, respectively, regrouped as necessary.

For SUVEN PHARMACEUTICALS LTD



Place : Hyderabad
Date: 8th June 2021

VENKAT JASTI
Chairman & MD
DIN: 00278028

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2021	31/03/2020	31/03/2021	31/03/2020
	Audited	Audited	Audited	Audited
ASSETS				
Non-current assets				
(a) Property, Plant and Equipment	43,706.51	35,306.20	43,706.51	35,306.20
(b) Capital Work-in-Progress	9,614.91	10,156.15	9,614.91	10,156.15
(c) Other Intangible Assets	241.75	279.59	241.75	279.59
(d) Intangible assets under development	17.30	14.37	17.30	14.37
(e) Right of use of assets	167.53	88.58	167.53	88.58
(f) Financial Assets				
I. Investments	24,564.73	24,564.73	36,119.40	30,745.81
II. Loans	6.20	6.00	6.20	6.00
III. Other Financial Assets	495.18	474.87	495.18	474.87
(g) Deferred tax assets (net)	-	-	-	-
(h) Other non current assets	599.21	1,045.08	599.21	1,045.08
Total Non-Current assets	79,413.32	71,935.57	90,967.99	78,116.65
Current assets				
(a) Inventories	20,108.04	17,487.22	20,108.04	17,487.22
(b) Financial Assets				
I. Investments	18,059.38	3,067.33	18,059.38	3,067.33
II. Trade Receivables	10,238.22	11,719.58	10,238.22	11,719.58
III. Cash and Cash equivalents	709.14	1,157.68	718.22	1,169.53
IV. Bank balances other than (III) above	247.10	237.97	247.10	237.97
V. Loans	21.78	20.39	21.78	20.39
VI. Other Financial assets	-	-	-	-
(c) Current Tax asset(net)	224.67	-	224.67	-
(d) Other current assets	6,861.11	5,462.38	6,861.11	5,462.74
Total Current assets	56,469.44	39,152.55	56,478.52	39,164.76
TOTAL - ASSETS	135,882.76	111,088.12	147,446.51	117,281.41
EQUITY AND LIABILITIES				
EQUITY				
(a) Equity Share Capital	2,545.65	1,272.82	2,545.65	1,272.82
(b) Other Equity	103,972.68	77,010.16	115,535.18	83,203.45
Equity attributable to owners of the company	106,518.33	78,282.98	118,080.83	84,476.27
LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	73.90	51.19	73.90	51.19
II. Borrowings	3,559.09	9,125.25	3,559.09	9,125.25
(b) Provisions	664.60	831.46	664.60	831.46
(c) Deferred tax Liabilities (net)	3,093.29	2,759.72	3,093.29	2,759.72
(d) Other non current liabilities	-	-	-	-
Total non-current liabilities	7,390.88	12,767.62	7,390.88	12,767.62
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	106.82	40.41	106.82	40.41
II. Borrowings	10,563.76	9,403.80	10,563.76	9,403.80
III. Trade payables				
a) To Micro & Small Enterprises	996.25	263.13	996.25	263.13
b) Other than Micro & Small Enterprises	7,296.89	6,842.44	7,296.89	6,842.44
IV. Other Financial Liabilities	2,522.75	2,319.89	2,524.00	2,319.89
(b) Current Tax liabilities (Net)	-	525.36	-	525.36
(c) Other Current liabilities	226.36	390.84	226.36	390.84
(d) Provision Employee benefits	260.72	251.65	260.72	251.65
	21,973.55	20,037.52	21,974.80	20,037.52
Total Liabilities	29,364.43	32,805.14	29,365.68	32,805.14
TOTAL - EQUITY AND LIABILITIES	135,882.76	111,088.12	147,446.51	117,281.41



For Suvphenarmaceuticals Ltd


 Venkat Jasti
 Chairman & MD

 Place : Hyderabad
 Date: 8th June, 2021

SUVEN PHARMACEUTICALS LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2021

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars		For the year ended 31st March 2021	For the year ended 31st March 2020
A. Cash flow from operating activities			
Profit before tax		41,397.92	35,759.03
Adjustments :			
Depreciation and amortisation expense		3,122.07	2,368.29
Interest Income		(26.79)	(36.06)
Finance Cost		914.37	1,866.23
Gain on sale of Current Investment		(332.77)	(623.12)
Debit balances writtenoff		72.16	13.35
Effects of foreign exchange rates (Unrealized)		(97.56)	(253.69)
Loss/(Profit) on disposal of Property,plant & equipment		(3.36)	-
Operating profit before working capital changes		45,046.06	39,094.03
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		1,336.08	3,461.83
Inventories		(2,620.82)	(1,777.39)
Other non current assets		(78.95)	(88.58)
Other current assets		(1,269.92)	1,044.23
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		1,194.52	1,712.89
Long term provisions		(166.86)	236.93
Short term provision		(102.78)	(23.49)
Changes In Lease Liability		89.12	91.59
Other financial liabilities		654.28	899.77
Other current liabilities		(164.48)	(136.27)
Cash generated from operating activities		43,916.24	44,515.55
Income taxes paid (net of refunds)		10,943.58	8,640.92
Net Cash flows from operating activities	(A)	32,972.66	35,874.63
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(11,084.60)	(10,306.61)
Proceeds from sale of Property, plant & equipment		3.36	13.43
Changes in Investments		-	(24,557.68)
Fixed deposits/margin money-placed/matured		(20.31)	(37.17)
Sale/(purchase) of mutual funds		(14,659.28)	(1,738.10)
Bank balances not considered as cash and cash equivalents		(5.12)	(38.61)
Net cash flow from /(used in) investing activities	(B)	(25,765.95)	(36,664.75)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(5,472.65)	9,125.25
(Repayment)/Proceeds from short term borrowings		1,230.17	968.67
Other non current financial assets		(0.20)	1.23
Other current financial assets		(1.39)	(9.62)
Finance Cost		(892.36)	(1,591.85)
Interest received		26.79	36.06
Dividends paid to equity holders (including dividend distribution tax)		(2,545.65)	(7,672.29)
Net cash flow from /(used In) financing activities	(C)	(7,655.29)	857.45
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	(448.57)	67.33
Cash and cash equivalents as at the beginning of the year		1,157.68	1,090.30
equivalents		0.03	0.06
Cash and cash equivalents at the end of the year		709.14	1,157.68

Place : Hyderabad
Date : 08th June 2021



For Suvén Pharmaceuticals Ltd

Venkateswarlu Jasti

Venkateswarlu Jasti
Chairman & M D
DIN: 00278028

SUVEN PHARMACEUTICALS LIMITED

Consolidated Statement of Cash flows for the year ended 31st March, 2021

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars		For the year ended 31st March 2021	For the year ended 31st March 2020
A. Cash flow from operating activities			
Profit before tax		46,767.41	40,451.18
Adjustments :			
Depreciation and amortisation expense		3,122.07	2,368.29
Interest Income		(26.79)	(36.06)
Finance Cost		914.37	1,991.52
Gain on sale of Current Investment		(332.77)	(623.12)
Debit balances writtenoff		72.16	13.35
Effects of foreign exchange rates (Unrealized)		(97.56)	(253.69)
Loss/(Profit) on disposal of Property,plant & equipment		(3.36)	-
Operating profit before working capital changes		50,415.54	43,911.47
Adjustments for (Increase)/decrease in operating assets			
Trade Receivables		1,336.08	3,461.83
Inventories		(2,620.82)	(1,777.39)
Other non current assets		(78.95)	(88.58)
Other current assets		(1,269.55)	1,043.86
Adjustments for Increase/(decrease) in operating liabilities			
Trade Payables		1,194.52	1,712.89
Long term provisions		(166.86)	236.93
Short term provision		(102.78)	(23.49)
Changes In Lease Liability		89.12	91.59
Other financial liabilities		655.53	899.77
Other current liabilities		(164.48)	(136.27)
Cash generated from operating activities		49,287.35	49,332.62
Income taxes paid (net of refunds)		10,943.58	8,640.92
Net Cash flows from operating activities	(A)	38,343.77	40,691.70
B. Cash flow from Investing activities			
Payments for Purchase of property, plant and equipment		(11,084.60)	(10,306.61)
Proceeds from sale of Property, plant & equipment		3.36	13.43
Changes in Investments		(5,373.60)	(30,738.76)
Foreign currency translation reserve		(0.27)	1,501.14
Fixed deposits/margin money-placed/matured		(20.31)	(37.17)
Sale/(purchase) of mutual funds		(14,659.28)	(1,738.10)
Bank balances not considered as cash and cash equivalents		(5.12)	(38.61)
Net cash flow from /(used in) investing activities	(B)	(31,139.82)	(41,344.69)
C. Cash flows from financing activities			
(Repayment)/Proceeds from long term borrowings		(5,472.65)	9,125.25
(Repayment)/Proceeds from short term borrowings		1,230.17	968.67
Other non current financial assets		(0.20)	1.23
Other current financial assets		(1.39)	(9.62)
Finance Cost		(892.36)	(1,717.14)
Interest received		26.79	36.06
Dividends paid to equity holders (including dividend distribution tax)		(2,545.65)	(7,672.29)
Net cash flow from /(used In) financing activities	(C)	(7,655.29)	732.16
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	(451.33)	79.18
Cash and cash equivalents as at the beginning of the year		1,169.53	1,090.30
equivalents		0.03	0.06
Cash and cash equivalents at the end of the year		718.22	1,169.53

For Suven Pharmaceuticals Ltd



Venkateswarlu Jasti
Venkateswarlu Jasti
 Chairman & M D
 DIN: 00278028

Place : Hyderabad
 Date : 08th June 2021



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2021 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2021 (refer 'Other Matters' section below) which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2021 ("the Statement") of SUVEN PHARMACEUTICALS LIMITED ("the Company"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2021:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive Income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2021

With respect to the Standalone Financial Results for the quarter ended March 31, 2021, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2021, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2021

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by



08/06/2021

the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2021 under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2021 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2021 that give a true and fair view of the net profit and other comprehensive Income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and Fairview and is free from material misstatement, whether due to fraud or error.


In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for

(a) Audit of the Standalone Financial Results for the year ended March 31, 2021

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2021 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error, and are considered material if, individually or



08/06/2021

in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained upto the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.



08/06/2021

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2021

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2021 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- These standalone financial results incorporate the relevant returns of foreign branch audited by the other auditors specifically appointed for this purpose, Whose financial information reflect total assets of Rs.319.15 lakhs as at March 31, 2021 and total revenues of Rs.NIL for the year ended March 31, 2021, total net loss of Rs.(760.96) lakhs for year ended March 31, 2021
- Attention is drawn to Note 10 to the Statement which states that the Standalone Financial Results includes the results for the Quarter ended March 31, 2021 being the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the current financial year Our report is not modified in respect of this matter.
- Attention is drawn to Note 10 to the Statement, the figures for the corresponding quarter ended March 31, 2020 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2019. We have not issued separate limited review report on the



08/06/2021

results and figures for the quarter ended March 31, 2020. Our report is not modified in respect of this matter.

For **KARVY & CO.,**
Chartered Accountants
(Firm Registration No. 001757S)



AJAYKUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 21021989AAAABY2695



Place: Hyderabad
Date : 08/06/2021

08/06/2021



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SUVEN PHARMACEUTICALS LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2021 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2021 (refer "Other Matters" section below), which were subject to limited review by us, both included in the accompanying "Consolidated Financial Results for the quarter and year ended March 31, 2021" of **SUVEN PHARMACEUTICALS LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") and its share of the net profit after tax and total comprehensive income of its associate company for the quarter and year ended March 31, 2021, (the "Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on financial information of the subsidiary and associate referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2021:


- (i) Includes the results of the following entities:

Name of the Company	Country	Relationship
SUVEN PHARMA INC	USA	Wholly Owned Subsidiary
RISING PHARMA HOLDINGS INC	USA	Associate

- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group and its associate for the year ended March 31, 2021.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2021

With respect to the Consolidated Financial Results for the quarter ended March 31, 2021, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended March 31, 2021 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated



08/06/2021

Financial Results for the quarter ended March 31, 2021, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2021


We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under Section 143(10) of the Companies Act, 2013 (the “Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“ICAI”) together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2021 under the provisions of the Act and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management’s Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent’s Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2021, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2021 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group, its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters



08/06/2021

related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associate are responsible for overseeing the financial reporting process of the Group and associate.

Auditor's Responsibilities for

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2021

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2021 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.



08/06/2021

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Information of the entities within the Group and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of entities included in the Annual Consolidated Financial Results of which we are the independent auditors .For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.


We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2021

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2021 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.



08/06/2021

As part of annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- Attention is drawn to Note 10 to the Statement which states that the Consolidated Financial Results includes the results for the Quarter ended March 31, 2021 being the balancing figure between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the current financial year .Our report is not modified in respect of this matter.
- Attention is drawn to Note 10 to the Statement, the figures for the corresponding quarter ended March 31, 2020 are the balancing figures between the annual audited figures for the year then ended and the year to date figures for the 9 months period ended December 31, 2019. We have not issued separate limited review report on the results and figures for the quarter ended March 31, 2020. Our report is not modified in respect of this matter.
- We did not audit the financial information of the subsidiary included in the consolidated financial results, whose financial information reflect total assets of Rs.36121.44 lakhs as at March 31, 2021 and total revenues of Rs.-NIL- and Rs.-NIL- Lakhs for the quarter and year ended March 31, 2021 respectively, total Net Loss after tax of (Rs.0.22)Lakhs and (Rs.4.11)Lakhs for the quarter and year ended March 31, 2021 respectively and total Comprehensive Loss of Rs.(0.22) Lakhs and (Rs.4.11) Lakhs for the quarter and year ended March 31, 2021 respectively and net cash flows of (Rs.2.76) Lakhs for the year ended March 31, 2021, as considered in the Statement .The consolidated financial results also includes the Group's share of profit after tax of Rs.1866.60 lakhs and Rs. 5373.60 Lakhs for the quarter and year ended March 31, 2021 respectively, as considered in the Statement, in respect of the associate whose financial information has not been audited by us. These financial information have been audited, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary and associate is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **KARVY & CO.,**
Chartered Accountants
(Firm Registration No. 001757S)



AJAYKUMAR KOSARAJU
Partner
Membership No. 021989
UDIN: 21021989AAAABZ2020



Place: Hyderabad
Date : 08/06/2021

08/06/2021

CSD/SE/BM/2021-22
June 8, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,


Sub: Declaration pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

.....

We hereby declare that the Statutory Auditors of the Company, M/s. Karvy & Co., (FRN: 001757S) Chartered Accountants have issued an Audit Reports with unmodified opinion on audited financial results of the company (Standalone and Consolidated) for the year ended 31st March, 2021.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**


Venkateswarlu Jasti
Chairman & Managing Director



Suven Pharmaceuticals Limited

Regd. Office : 8-2-334, SDE Serene Chambers, 3rd Floor, Road No 5, Avenue 7,
Banjara Hills, Hyderabad - 500034. Telangana, India. CIN : L24299TG2018PLC128171
Tel: 91 40 2354 9414, Fax : 91 40 2354 1152, Email: info@suvenpharm.com, Website: www.suvenpharm.com

NEWS RELEASE

HYDERABAD, INDIA (8 June' 2021) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 March' 2021. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 8 June' 2021 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Year ended	
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
Revenue	2,624.63	2,797.76	1,901.05	10,239.56	8,519.07
EBITDA	969.91	1,421.77	819.16	4,547.59	3,997.60
EBITDA Margin	36.95%	50.82%	43.09%	44.41%	46.93%
EBIT	886.76	1,334.20	749.52	4,231.23	3,762.53
EBIT Margin	33.79%	47.69%	39.43%	41.32%	44.17%
Finance costs	18.70	19.10	65.12	91.44	186.62
Depreciation	83.15	87.58	69.64	316.36	235.07
Taxes	223.54	338.75	151.99	1,053.32	875.10
Taxes to PBT	25.75%	25.76%	22.21%	25.44%	24.47%
PAT (Standalone)	644.52	976.35	532.41	3,086.47	2,700.80
PAT Margin (Standalone)	24.56%	34.90%	28.01%	30.14%	31.70%
Associate Company	186.66	160.00	209.69	537.36	482.13
PAT (Consolidated)	831.16	1,136.25	741.82	3,623.42	3,170.02
PAT Margin (Consolidated)	31.67%	40.61%	39.02%	35.39%	37.21%
EPS (Standalone)	2.53	3.84	2.09	12.12	10.61
EPS (Consolidated)	3.27	4.46	2.91	14.23	12.45
Paid up share capital (Re.1/sh)	254.56	254.56	127.28	254.56	127.28

Growth Ratios

	Quarter ended 31 Mar 21 to 31 Dec 20	Quarter ended 31 Mar 21 to 31 Mar 20	Year ended 31 Mar 21 to 31 Mar 20
Growth in income	-6.19%	38.06%	20.20%
Growth in EBITDA	-31.78%	18.40%	13.76%
Growth in EBIT	-33.54%	18.31%	12.46%
Growth in PAT Standalone	-33.99%	21.06%	14.28%
Growth in PAT Consolidated	-26.85%	12.04%	14.30%

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).

Suven Pharmaceuticals Limited

2. The Board has recommended a Final Dividend of Re.1.00 per share of face value of Rs.1.00 each (100%) for approval of members in the ensuing AGM of the Company. With this the total dividend for the year ending March 2021 stood at Re.2.00 per share of face of value of Rs.1.00 each (200%).
3. The Board has allotted the Bonus shares at 1:1 ratio in its Board meeting held on 29 September' 2020. Accordingly, the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated.
4. The COVID-19 did have some impact on the business and research operations in India starting March 2021 and continues to impact in terms of employee absenteeism (around 20%), adjustment of shifts due to lock down, material movements and increase in raw material and logistics cost due to shortage of oxygen. However, there was no major impact on our subsidiary, Suven Pharma, Inc., USA.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited